Max Planck Institute of Psychiatry, Munich, Germany.
World J Biol Psychiatry. 2010 Mar;11(2):110-20. doi: 10.3109/15622970903490626.
Proteome analysis has emerged as a promising strategy to the identification of potential biomarkers and to further confirm the importance of certain pathways in the schizophrenia (SCZ) pathophysiology. Reviewing the results of 13 proteome studies in SCZ brain tissue, we aimed to provide information regarding potential proteins biomarkers as well as information about the pathophysiology of the disease.
Using two-dimensional gel electrophoresis and shotgun mass spectrometry, 31 proteins were consistently found differentially expressed in the brains of SCZ patients. The most frequent protein alterations reported in SCZ were related to brain energy metabolism, brain plasticity, and synaptic function, processes that are thought to belong to the core of the biology of this disease. The recurrent identification and validation of inter-related protein clusters, determined in different samples and approaches, strongly reinforces the putative involvement of certain pathways in SCZ.
The availability of reliable markers not only paves the way to the development of new therapeutic strategies but also points out the possibility of their use as peripheral blood markers that may potentially contribute to the early SCZ detection and early therapeutic intervention, both of which can reduce the social and cognitive consequences of the disease.
蛋白质组分析已成为鉴定潜在生物标志物的一种很有前途的策略，并进一步证实某些途径在精神分裂症（SCZ）发病机制中的重要性。我们回顾了 13 项 SCZ 脑组织蛋白质组研究的结果，旨在提供有关潜在蛋白生物标志物的信息以及有关疾病发病机制的信息。
使用二维凝胶电泳和鸟枪法质谱，在 SCZ 患者的大脑中发现了 31 种一致表达差异的蛋白质。在 SCZ 中报道的最常见的蛋白质改变与脑能量代谢、脑可塑性和突触功能有关，这些过程被认为属于该疾病生物学的核心。在不同样本和方法中确定的反复出现的相互关联的蛋白质簇的识别和验证，强烈支持某些途径在 SCZ 中的潜在参与。
可靠标志物的出现不仅为开发新的治疗策略铺平了道路，而且还指出了它们作为外周血标志物的使用可能性，这可能有助于早期 SCZ 的检测和早期治疗干预，从而减少疾病的社会和认知后果。
